
ZTS — Zoetis Inc
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic
$76.64
-$0.46 (-0.59%)
Zoetis Inc (ZTS) is a drug manufacturers - specialty & generic company listed on NYSE. It is led by Kristin C. Peck, based in 10 Sylvan Way, Parsippany, NJ, United States, 07054, with about 13,800 employees. Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1950 and is headquartered in Parsippany, New Jersey.
Latest reported ZTS revenue for 2025-09-30 was $2.40B. Net income was $721.0M. Revenue was down 2.4% from 2025-06-30 to 2025-09-30. ZTS currently screens at market cap $64.65B and trailing P/E 24.9.
Use this ZTS page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ZTS quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ZTS SEC filings page. Lician reads the product cache first so this HTML stays unique to Zoetis Inc even when a live quote feed is slow.
About Zoetis Inc
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1950 and is headquartered in Parsippany, New Jersey.
ZTS Key Statistics
Market Cap
$64.65B
P/E Ratio
24.90
Dividend Yield
1.28%
Employees
13,800
Zoetis Inc Company Information
- CEO & Director
- Kristin C. Peck
- Headquarters
- 10 Sylvan Way, Parsippany, NJ, United States, 07054
- Website
- www.zoetis.com
- Phone
- 973 822 7000
- IPO / Founded
- 2013-02-01
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic